Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

688.80 11.86 +1.75%
Market cap
$250.8B
P/E
35.8×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

5 4 4 7
ROE
13.02% 13.52% 13.51% 13.37%
ROA
6.46% 6.45% 6.50% 6.51%
ROIC
6.12% 5.56% 5.80% 6.03%
Return on Tangible Assets
27.84% 37.31% 36.57% 32.11%
Average Days of Receivables
72.91 74.33 74.45 74.19
Free Cash Flow per Share
16.81 18.25 19.84 20.64
Free Cash Flow
6,337.00 6,789.00 7,362.00 7,637.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 3 Nov 2026